Compatibility between Upfront’s Rhobust technology and Cangene’s manufacturing process will be determined for eventual clinical trial production.

Upfront Chromatography and Cangene will jointly develop a high-yield process for the isolation of human and equine IgG directly from blood plasma. Upfront’s says that initial testing has demonstrated the successful capture of IgG from plasma using its processing platform.


“The project will incorporate a process-development and scale-up phase in order to produce material suitable for clinical trials and to determine the compatibility with Cangene’s manufacturing processes,” says Allan Lihme, technical director of Upfront.


“The implementation of Upfront’s Rhobust platform has the potential to minimise the process steps required for the isolation of IgG from blood plasma and maximise yield and plant capacities at Cangene’s multiproduct facilities.”

Previous articleFuture Fuel Cells
Next articleOneWorld Health, Amyris, and Sanofi-Aventis to Create a Complementary Source for Key Ingredient of Malaria Therapy